Cancer

Cancer Screening: What to Check at Every Age

The Pin Health Staff Writer

February 20, 2026 18 min read

Most cancers don't cause symptoms until they've been growing for years. By the time you feel something, the window for early treatment may already be narrowing. Screening exists to find cancer before that point — when it's smallest, most treatable, and most curable.

Cancer is not one disease — it’s hundreds. But nearly all of them share one thing in common: the earlier they’re found, the better the outcome. For many cancers, the difference between early and late detection is the difference between a routine treatment and a life-threatening diagnosis.

The challenge is that most cancers don’t announce themselves. They don’t cause pain in the early stages. They don’t produce obvious symptoms until the tumour has been growing — sometimes for years. By the time something feels wrong, the cancer may have already spread beyond its site of origin, dramatically reducing treatment options and survival rates.

This is precisely why screening exists. Cancer screening is the practice of testing for cancer in people who have no symptoms — finding it before it becomes dangerous. It’s not about being paranoid. It’s about being strategic. And the data is unambiguous: for the cancers where effective screening exists, early detection saves lives. Moreover, the gap between screened and unscreened populations in survival rates continues to widen as screening technologies improve.

However, screening isn’t one-size-fits-all. The right tests depend on your age, sex, family history, and personal risk factors. Getting screened too early wastes resources and can cause unnecessary anxiety. Getting screened too late misses the window where detection matters most. This article walks through what’s recommended at each stage of life — and what blood tests can add to the picture.

Why Early Detection Matters So Much

Cancer staging — the system doctors use to describe how advanced a cancer is — directly predicts survival. Stage I cancers (localised, small, not spread) are frequently curable with surgery alone. Stage IV cancers (spread to distant organs) are typically manageable but rarely curable. The gap in survival between these stages is enormous.

Consider a few examples. The five-year survival rate for stage I breast cancer exceeds 99%. For stage IV, it drops to approximately 30%. Stage I colorectal cancer has a five-year survival rate above 90%. Stage IV is closer to 15%. Stage I lung cancer survival approaches 65-80%. Stage IV is below 10%. These are not subtle differences — they represent fundamentally different prognoses. More importantly, the primary variable determining which stage you’re diagnosed at is whether screening caught the cancer before symptoms appeared.

In other words, screening doesn’t just find cancer. It finds it at the point where treatment is most likely to succeed. That distinction changes everything.

Screening in Your 20s and 30s

Cancer is relatively rare in younger adults, and broad screening for every cancer type isn’t necessary or recommended at this age. Even so, several targeted screenings should begin during this period — and establishing baseline health markers creates a reference point for future comparison.

Cervical cancer screening

Cervical cancer screening is one of the great success stories of preventive medicine. Regular screening has reduced cervical cancer deaths by more than 70% in countries with established programmes. Current guidelines recommend starting cervical screening at age 25 in most countries, though some guidelines begin at 21.

The primary screening tools are the Pap smear (which detects abnormal cervical cells) and HPV testing (which detects the human papillomavirus strains responsible for virtually all cervical cancers). Many guidelines now recommend HPV testing as the primary screening method, with Pap smears used as a follow-up when needed. Screening intervals vary by method — typically every three years for Pap smears alone, or every five years for HPV testing or co-testing.

It’s worth noting that HPV vaccination has dramatically reduced cervical cancer rates in vaccinated populations. That said, vaccination doesn’t eliminate the need for screening — it reduces risk but doesn’t eliminate it entirely. Consequently, regular cervical screening remains important regardless of vaccination status.

Skin awareness

Skin cancer is the most common cancer overall, and melanoma — the most dangerous form — can occur at any age. While formal skin screening recommendations vary by country, dermatologists generally advise regular self-examination of moles and skin lesions starting in early adulthood. In particular, the ABCDE rule (Asymmetry, Border irregularity, Colour variation, Diameter, Evolution) provides a practical framework for identifying suspicious changes.

People with fair skin, a history of sunburns, many moles, or a family history of melanoma should be particularly vigilant. For these individuals, annual professional skin examinations may be appropriate even in their 20s and 30s.

Testicular self-examination

Testicular cancer is the most common cancer in men aged 15-35. Unlike many cancers, it’s often detected by the individual rather than through formal screening. Regular self-examination — checking for lumps, swelling, or changes in size or texture — is a simple and effective practice. Testicular cancer is highly curable even when advanced, but early detection still simplifies treatment significantly.

Baseline blood work

While there’s no general cancer blood test recommended for low-risk young adults, establishing baseline values for key health markers during your 20s and 30s creates a reference point that becomes valuable later. A complete blood count (CBC), liver function tests, kidney function markers, and inflammatory markers like CRP provide a snapshot of normal function. Deviations from your personal baseline in future years can prompt earlier investigation than population-based reference ranges alone would trigger.

Screening in Your 40s

Cancer risk begins to increase meaningfully in the 40s, and several important screening programmes either begin or should be discussed with a healthcare provider during this decade.

Breast cancer screening

Breast cancer is the most commonly diagnosed cancer in women worldwide. Screening recommendations have evolved significantly and currently vary between countries and guidelines bodies — reflecting ongoing debate about the optimal balance between early detection and overdiagnosis.

Most major guidelines now recommend that women begin regular mammography screening between ages 40 and 50. Specifically, some organisations recommend annual mammograms starting at 40, while others suggest beginning at 45 or 50 with biennial screening. The variation reflects differences in how each guideline weighs the benefits of earlier detection against the risks of false positives and unnecessary procedures.

What’s less debated is that women with elevated risk — those with a first-degree relative with breast cancer, known BRCA1/BRCA2 mutations, or prior chest radiation — should begin screening earlier and may benefit from additional modalities such as breast MRI. A risk assessment conversation with a healthcare provider in the early 40s (or earlier for high-risk women) helps determine the most appropriate screening schedule.

Colorectal cancer screening

Colorectal cancer is the third most common cancer globally and one of the most preventable through screening. Notably, in a significant shift, many guidelines have recently lowered the recommended starting age for colorectal screening from 50 to 45, reflecting rising rates of colorectal cancer in younger adults.

Several screening methods are available, each with different advantages:

Colonoscopy is considered the gold standard. It allows direct visualisation of the entire colon, and precancerous polyps can be removed during the procedure itself — making it both a screening and prevention tool. If results are normal, repeat screening is typically recommended every ten years.

Stool-based tests — including the faecal immunochemical test (FIT) and stool DNA tests — offer non-invasive alternatives. These tests detect blood or abnormal DNA shed by polyps or cancers into the stool. They’re performed at home and require no preparation, but they need to be repeated more frequently (annually for FIT, every one to three years for stool DNA tests) and positive results require follow-up colonoscopy.

The best screening method is ultimately the one you’ll actually complete. In other words, for people who are hesitant about colonoscopy, stool-based tests provide a practical alternative that still detects the majority of cancers at an early stage. The key is starting at the recommended age and maintaining regular intervals.

Lung cancer screening

Lung cancer remains the leading cause of cancer death worldwide, largely because it’s typically diagnosed at an advanced stage. However, low-dose CT screening has been shown to reduce lung cancer mortality by approximately 20% in high-risk populations.

Current guidelines recommend annual low-dose CT scans for adults aged 50-80 (some guidelines start at 50, others at 55) who have a significant smoking history — generally defined as 20 or more pack-years — and who currently smoke or quit within the past 15 years. This is a targeted screening that applies specifically to people with substantial tobacco exposure. For never-smokers and light smokers, the risks of annual CT screening (radiation exposure, false positives) outweigh the benefits.

Screening in Your 50s and Beyond

Cancer incidence rises substantially after 50, making this the decade where comprehensive screening becomes most important. All previously initiated screenings should continue, and several additional considerations come into play.

Prostate cancer screening

Prostate cancer screening remains one of the most debated areas in preventive medicine. The PSA (prostate-specific antigen) blood test can detect prostate cancer early, but it also produces a high rate of false positives and can lead to overdiagnosis — identifying slow-growing cancers that would never have caused harm during the patient’s lifetime.

Current guidelines generally recommend a shared decision-making approach starting at age 50 for average-risk men (or age 40-45 for high-risk men, including those with a family history or of African descent). This means discussing the potential benefits and harms of PSA testing with a healthcare provider before deciding whether to proceed. The conversation should cover the possibility of false positives, the risk of overdiagnosis, and the potential consequences of subsequent procedures.

Despite the controversy, PSA testing does save lives when used thoughtfully. The key, however, is interpreting results in context — considering trends over time (PSA velocity), prostate size, age, and family history — rather than reacting to a single elevated number. A baseline PSA in the early 40s or 50s can also help risk-stratify future screening frequency.

Continued breast cancer screening

For women, mammography screening continues through the 50s, 60s, and 70s — typically biennially, though annual screening may be recommended for high-risk women. Breast cancer risk increases with age, making continued screening important. Most guidelines suggest continuing regular screening until at least age 74, with decisions beyond that point based on overall health and life expectancy.

Continued colorectal screening

Colorectal screening remains essential through the 50s and 60s. If you’re up to date on colonoscopy or stool-based testing, maintain the recommended schedule. If you haven’t started, begin immediately — colorectal cancer incidence peaks between 65 and 74, and screening at this age prevents the most deaths. Most guidelines recommend continuing until age 75, with decisions about screening beyond 75 based on individual health and prior screening history.

Other cancers to be aware of

Liver cancer: People with chronic hepatitis B, chronic hepatitis C, or established liver cirrhosis should undergo regular liver cancer surveillance — typically with ultrasound and alpha-fetoprotein (AFP) blood testing every six months. This applies at any age once risk factors are present, but becomes increasingly important after 50.

Stomach cancer: In regions with high stomach cancer rates (East Asia, parts of South America, Eastern Europe), screening with endoscopy may be recommended. Helicobacter pylori testing and treatment also reduces risk. In lower-risk populations, routine stomach cancer screening isn’t generally recommended, but persistent digestive symptoms should always be investigated.

Pancreatic cancer: No effective population-level screening currently exists for pancreatic cancer. However, individuals with a strong family history (two or more first-degree relatives) or known genetic syndromes (such as BRCA2, PALB2, or hereditary pancreatitis) may benefit from surveillance with endoscopic ultrasound and MRI at specialised centres.

The Role of Blood Tests in Cancer Detection

Blood tests have always played a supporting role in cancer detection, and that role is expanding. While no blood test alone can definitively diagnose cancer, several markers provide valuable signals — either as screening tools for specific cancers or as indicators that further investigation is warranted.

Established tumour markers

PSA (Prostate-Specific Antigen): The most widely used cancer blood marker. As discussed above, PSA screening for prostate cancer has clear benefits but also limitations. It’s most useful when tracked over time rather than interpreted as a single value.

CA-125: Elevated in many cases of ovarian cancer, but also in numerous benign conditions. It’s not recommended as a general screening tool due to limited specificity. However, in women with known high risk (BRCA mutations, strong family history), serial CA-125 combined with transvaginal ultrasound may be used as part of a surveillance strategy.

AFP (Alpha-Fetoprotein): Used in surveillance of high-risk patients for liver cancer (hepatocellular carcinoma). Most valuable when combined with imaging in patients with cirrhosis or chronic hepatitis.

CEA (Carcinoembryonic Antigen): Primarily used for monitoring colorectal cancer after treatment rather than for initial screening. Elevated levels can indicate recurrence, making it valuable in follow-up care.

Multi-cancer early detection tests

One of the most significant developments in cancer screening is the emergence of multi-cancer early detection (MCED) blood tests. These tests analyse circulating cell-free DNA, proteins, or other biomarkers shed by tumours into the bloodstream, with the goal of detecting multiple cancer types from a single blood draw.

Several MCED tests are currently in development or have received limited approval. The most advanced have demonstrated the ability to detect over 50 cancer types — including many for which no standard screening exists (such as pancreatic, liver, and ovarian cancers). Furthermore, these tests can often identify the tissue of origin, guiding follow-up investigation.

However, it’s essential to understand the current limitations. Sensitivity varies significantly by cancer type and stage — these tests are generally better at detecting later-stage cancers than early-stage ones, though performance is improving with each iteration. False positives occur and can lead to anxiety and unnecessary follow-up procedures. Additionally, the clinical evidence demonstrating that MCED tests reduce cancer mortality is still being established through large-scale trials.

Nevertheless, the trajectory is clear. Multi-cancer blood tests represent a fundamentally new approach to cancer screening — one that could eventually complement or even replace some traditional screening methods. For now, they’re best viewed as an additional layer of screening rather than a replacement for established programmes.

Inflammatory and metabolic markers

While not cancer-specific, certain blood markers can provide indirect signals that warrant further investigation:

C-reactive protein (CRP) and ESR: Persistent, unexplained elevation of inflammatory markers — after ruling out infection, autoimmune conditions, and other causes — can occasionally be an early signal of malignancy. Chronic inflammation itself is also a cancer risk factor, making these markers relevant to long-term risk assessment.

Complete blood count (CBC): Unexplained changes in blood cell counts — particularly persistent anaemia, elevated white blood cells, or abnormal platelet counts — can be among the earliest detectable signs of blood cancers (leukaemia, lymphoma, myeloma) or cancers that have metastasised to bone marrow. A CBC is simple, inexpensive, and provides broad screening value.

Liver function tests (LFTs): Unexplained elevations in liver enzymes — particularly in the context of weight loss, fatigue, or other systemic symptoms — can indicate primary liver cancer or metastatic disease affecting the liver.

LDH (Lactate Dehydrogenase): A nonspecific marker that can be elevated in various cancers, particularly lymphomas and metastatic disease. Useful as part of a broader diagnostic workup when cancer is suspected.

The value of these markers lies not in isolation but in context. An elevated CRP in an otherwise healthy person may mean nothing. An elevated CRP combined with unexplained weight loss, anaemia, and fatigue tells a very different story. Comprehensive blood panels create a picture where individual abnormalities gain meaning through their relationship to each other.

Family History and Genetic Risk

Family history is one of the most powerful tools for cancer risk assessment — and one of the most underutilised. A first-degree relative (parent, sibling, or child) with cancer increases your risk for that cancer type, and the risk rises further with multiple affected relatives or early-onset diagnoses.

When to consider genetic testing

Genetic counselling and testing may be appropriate if your family history includes any of the following patterns:

• Multiple relatives on the same side of the family with the same cancer type
• Cancer diagnosed before age 50 in a close relative
• A relative with more than one primary cancer
• Known hereditary cancer syndromes in the family (BRCA1/2, Lynch syndrome, Li-Fraumeni, familial adenomatous polyposis)
• Certain ethnic backgrounds with higher prevalence of specific mutations (e.g., Ashkenazi Jewish heritage and BRCA mutations)

Identifying a hereditary cancer predisposition allows for significantly enhanced screening — starting earlier, screening more frequently, and using more sensitive modalities. In some cases, it also opens the door to preventive interventions that dramatically reduce risk. To illustrate, women with BRCA1 mutations can reduce breast cancer risk by more than 90% through prophylactic surgery, and individuals with Lynch syndrome can reduce colorectal cancer risk through increased surveillance and aspirin use.

Screening adjustments for high-risk individuals

If genetic testing reveals elevated risk, screening protocols are typically intensified. This may include starting mammography or colonoscopy a decade earlier than standard recommendations, adding MRI to breast screening, shortening screening intervals, or adding screening for cancers not covered by standard population-level programmes. These personalised protocols can be lifesaving for people who would otherwise be told they’re “too young” for screening under standard guidelines.

Building Your Screening Strategy

Effective cancer screening isn’t about doing every test available. It’s about matching the right tests to your individual risk profile and maintaining them consistently over time. Here’s how to approach it:

Know your family history in detail. Document cancer diagnoses in first- and second-degree relatives, including the type of cancer and age at diagnosis. Share this information with your healthcare provider. This single step can determine whether you need enhanced screening, genetic counselling, or earlier initiation of standard tests.

Follow age-appropriate guidelines. Start cervical screening at 25, colorectal screening at 45, breast screening between 40-50 (or earlier if high risk), and discuss prostate screening at 50 (or 40-45 if high risk). These aren’t arbitrary numbers — they’re based on decades of data showing when screening produces the greatest benefit relative to risk.

Don’t skip or delay. Screening works best as a consistent programme, not as an occasional event. A colonoscopy that’s five years overdue has missed potential polyps that could have been removed. A mammogram that’s two years late may catch a cancer at stage II instead of stage I. Consistency is what transforms screening from a snapshot into a safety net.

Use blood work as a complement. Regular comprehensive blood panels — including CBC, liver and kidney function, inflammatory markers, and metabolic markers — provide a broad surveillance layer that can detect indirect signals of developing disease. While not cancer-specific, these tests are inexpensive, minimally invasive, and can prompt earlier investigation when results deviate from your established baseline.

Stay informed about emerging tests. Multi-cancer blood tests are advancing rapidly and may become a standard part of screening within the coming years. Discuss these options with your healthcare provider as they become available, particularly if you have elevated risk factors or a family history that places you beyond what standard screening covers.

Respond to symptoms promptly. Screening catches cancer before symptoms appear — but when symptoms do appear between screening intervals, don’t wait for your next scheduled test. Unexplained weight loss, persistent fatigue, changes in bowel habits, unusual bleeding, lumps, persistent pain, or any new symptom that doesn’t resolve within a few weeks warrants investigation. Early evaluation of concerning symptoms is itself a form of early detection.

---

Key Takeaways

• Early detection is the single most important factor in cancer survival — the difference between stage I and stage IV diagnosis can be the difference between cure and palliation
• Cervical screening should begin at age 25 — HPV testing combined with Pap smears has reduced cervical cancer deaths by over 70%
• Colorectal screening should start at age 45 — colonoscopy can both detect and prevent cancer by removing precancerous polyps
• Breast cancer screening typically begins between 40 and 50 — earlier for women with elevated risk factors or family history
• Lung cancer screening with low-dose CT is recommended for high-risk smokers — and reduces mortality by approximately 20%
• PSA screening for prostate cancer requires informed decision-making — benefits are real but must be weighed against overdiagnosis risk
• Blood tests provide valuable supporting signals — CBC, tumour markers, inflammatory markers, and liver function can all offer early clues
• Multi-cancer early detection blood tests are emerging rapidly — and may transform screening by covering dozens of cancer types from a single draw
• Family history is the most underused risk assessment tool — it determines whether standard screening is sufficient or enhanced protocols are needed
• Consistency matters more than any single test — screening is a long-term strategy, not a one-time event